- Home
- LXRX vs TALK Comparison
LXRX vs TALK Comparison
Compare LXRX & TALK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LXRX | TALK |
|---|---|---|
| Founded | 1995 | 2012 |
| Country | United States | United States |
| Employees | N/A | 521 |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Nursing Services |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 703.3M | 788.5M |
| IPO Year | 2000 | N/A |
Fundamental Metrics
Financial Performance| Metric | LXRX | TALK |
|---|---|---|
| Price | $2.32 | $5.19 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 6 |
| Target Price | $4.15 | ★ $6.42 |
| AVG Volume (30 Days) | ★ 2.9M | 1.3M |
| Earning Date | 05-01-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 77.78 | N/A |
| EPS | N/A | N/A |
| Revenue | ★ $49,803,000.00 | N/A |
| Revenue This Year | N/A | $26.02 |
| Revenue Next Year | N/A | $21.24 |
| P/E Ratio | ★ N/A | $155.55 |
| Revenue Growth | ★ 60.24 | N/A |
| 52 Week Low | $0.52 | $2.22 |
| 52 Week High | $2.53 | $5.20 |
Technical Indicators
Market Signals| Indicator | LXRX | TALK |
|---|---|---|
| Relative Strength Index (RSI) | 70.85 | 57.77 |
| Support Level | $1.44 | $4.59 |
| Resistance Level | N/A | $5.19 |
| Average True Range (ATR) | 0.16 | 0.02 |
| MACD | 0.08 | -0.01 |
| Stochastic Oscillator | 80.20 | 50.00 |
Price Performance
Historical ComparisonAbout LXRX Lexicon Pharmaceuticals Inc.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, and LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.
About TALK Talkspace Inc.
Talkspace Inc is a behavioral healthcare company offering access to licensed therapists, psychologists, and psychiatrists through its technology platform. It serves clients including health plans, enterprises, and individual subscribers. Therapists address various mental health conditions, while psychiatrists cater to a higher acuity demographic. Revenue stems from payor and direct-to-enterprise clients, with contracts lasting one to three years. The majority of the Company's operations and revenues are based in the United States.